Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
Loading...
Embargo End Date
ICR Authors
Authors
Gounder, M
Abdul Razak, AR
Gilligan, AM
Leong, H
Ma, X
Somaiah, N
Chawla, SP
Martin-Broto, J
Grignani, G
Schuetze, SM
Vincenzi, B
Wagner, AJ
Chmielowski, B
Jones, RL
Shah, J
Shacham, S
Kauffman, M
Riedel, RF
Attia, S
Abdul Razak, AR
Gilligan, AM
Leong, H
Ma, X
Somaiah, N
Chawla, SP
Martin-Broto, J
Grignani, G
Schuetze, SM
Vincenzi, B
Wagner, AJ
Chmielowski, B
Jones, RL
Shah, J
Shacham, S
Kauffman, M
Riedel, RF
Attia, S
Document Type
Journal Article
Date
2021-04-15
Date Accepted
2021-03-31
Abstract
Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials & methods: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Results were reported from baseline to day 169 (where exposure to treatment was maximized while maintaining adequate sample size). Results: Pain scores worsened for placebo versus selinexor across all postbaseline visits, although differences in HRQoL at some visits were not significant. Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time. Conclusion: Patients treated with selinexor reported lower rates and slower worsening of pain compared with patients who received placebo.
Citation
Future oncology (London, England), 2021
Source Title
Publisher
FUTURE MEDICINE LTD
ISSN
1479-6694
eISSN
1744-8301
Collections
Research Team
Sarcoma Clinical Trials (R Jones)
Sarcoma Clinical Trials (R Jones)
Sarcoma Clinical Trials (R Jones)